Abstract P4-12-06: Small HER2-positive breast carcinomas: Prognostic factors to consider in deciding on adjuvant trastuzumab treatment
| Autor: | Marianna Sasso, Sylvie Ménard, Manuela Campiglio, Elda Tagliabue, Marco Sandri, Federica Turdo, Francesca Bianchi |
|---|---|
| Rok vydání: | 2013 |
| Předmět: | |
| Zdroj: | Cancer Research. 73:P4-12 |
| ISSN: | 1538-7445 0008-5472 |
| DOI: | 10.1158/0008-5472.sabcs13-p4-12-06 |
| Popis: | Criteria for the decision to treat small tumors in adjuvant setting remain debatable, especially for HER2-positive tumors, since HER2 itself is associated with poor prognosis. Analysis of a large database including 503 T1 HER2-positive breast carcinomas treated with chemotherapy plus trastuzumab in Italian oncology clinics from 2006 to 2009 and, with 32 months of median follow-up and with 35 (7.0%) relapses, revealed no statistically significant differences in relapse rate among the T1a/T1micro, T1b and T1c groups, suggesting that tumor size is not associated with relapse probability in T1 HER2-positive tumors; the only clinico-pathological factors significantly associated with disease-free survival were nodal involvement (unadjusted HR = 3.4, 95%CI = 1.6-7.3, p = 0.002), loss of hormone receptor expression (HR = 3.1, 95%CI = 1.5-6.2, p = 0.002) and high tumor grade (HR = 2.9, 95%CI = 1.2-6.9, p = 0.020). Multivariate analysis indicated that patients who were both ER-negative and lymph node-positive presented the highest risk of relapse (HR = 5.5, 95%CI = 2.8-10.9, p = 1 cm, our data identify T1 tumor ER-negativity/axillary lymph node-positivity as the crucial criteria for adjuvant treatment, independent of tumor size categories. Supported by AIRC. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-12-06. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|